Cellular Immunotherapy For Prostate Cancer

Sipuleucel-T (Provenge) is a therapeutic agent used to treat asymptomatic or minimally symptomatic, castration-resistant, metastatic prostate cancer. The agent comprises specially treated dendritic cells obtained from the individual through leukapheresis. The cells are then exposed in vitro to proteins that contain prostate antigens and immunologic-stimulating factors and reinfused into the individual. The proposed mechanism of action is that treatment stimulates the individual's own immune system to resist cancer spread.